NDA 218275 · Istx
Zevtera
Ceftobiprole Medocaril Sodium · Intravenous
NovelPriority reviewCDER novel approval, Apr 3, 2024: To treat certain bloodstream infections, bacterial skin and associated tissue infections, and community-acquired bacterial pneumonia
Last checked: Nov 20, 2026Latest source record: Jun 26, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Apr 3, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
24
11 Phase 3, 0 recruiting
FAERS reports
57
55 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 13, 2026.
ZEVTERA is a cephalosporin antibacterial indicated for the treatment of: Adult patients with Staphylococcus aureus bloodstream infections (bacteremia) (SAB), including those with right-sided infective endocarditis ( 1.1 ), Adult patients with acute bacterial skin and skin structure infections (ABSSSI) ( 1.2 ), and Adult and pediatric patients (3 months to less than 18 years old) with community-acquired bacterial pneumonia (CABP) ( 1.3 ). To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZEVTERA and other antibacterial drugs, ZEVTERA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria ( 1.4 ). 1.1 Staphylococcus aureus Bloodstream Infection (Bacteremia) ZEVTERA is indicated for the treatment of adult patients with Staphylococcus aureus bloodstream infection (bacteremia) (SAB), including those with right-sided infective endocarditis, caused by methicillin-susceptible and methicillin-resistant isolates . 1.2 Acute Bacterial Skin and Skin Structure Infections ZEVTERA is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following gram-positive and gram-negative microorganisms: Staphylococcus aureus (methicillin-susceptible and methicillin-resistant isolates), Streptococcus pyogenes, and Klebsiella pneumoniae. 1.3 Community-Acquired Bacterial Pneumonia ZEVTERA is indicated for the treatment of adult and pediatric patients (3 months to less than 18 years old) with community-acquired bacterial pneumonia (CABP) caused by susceptible isolates of the following gram-positive and gram-negative microorganisms: Staphylococcus aureus (methicillin-susceptible isolates), Streptococcus...
Mechanism: ZEVTERA is an antibacterial drug [see Microbiology (12.4) ]
Therapeutic areas: Infectious disease and vaccines · Dermatology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 3, 2024 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
1 products under this application
- ZEVTERA · CEFTOBIPROLE MEDOCARIL SODIUM 667MG/VIAL · POWDER, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ceftobiprole Medocaril" as an intervention, any sponsor and status, largest first.
- Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure InfectionsPivotal-lookingCompleted
Basilea PharmaceuticaIndustry
NCT00210899 · 828 participants · Start Sep 2005 · Primary completion Oct 2006
Drug: ceftobiprole medocaril; Vancomycin plus Ceftazidime · For: Skin Diseases, Infectious; Skin Diseases, Bacterial; Staphylococcal Skin Infections
- Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure InfectionsPivotal-lookingCompleted
Basilea PharmaceuticaIndustry
NCT00228982 · 784 participants · Start Oct 2004 · Primary completion Dec 2005
Drug: Ceftobiprole medocaril; Vancomycin · For: Skin Diseases, Infectious; Skin Diseases, Bacterial; Staphylococcal Skin Infections
- Ceftobiprole in Hospital Acquired PneumoniaPivotal-lookingCompleted
Basilea PharmaceuticaIndustry
NCT00210964 · 781 participants · Start Apr 2005 · Primary completion May 2007
Drug: ceftobiprole plus placebo; linezolid plus ceftazidime · For: Pneumonia
- Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure InfectionsPivotal-lookingCompleted
Basilea PharmaceuticaIndustry
NCT03137173 · 679 participants · Start Feb 19, 2018 · Primary completion Apr 22, 2019
Drug: ceftobiprole medocaril; vancomycin+aztreonam · For: Acute Bacterial Skin and Skin Structure Infections
Sites: Anaheim, California; Chula Vista, California; Fresno, California · 34 sites in all
- Ceftobiprole in the Treatment of Patients With Community-Acquired PneumoniaPivotal-lookingCompleted
Basilea PharmaceuticaIndustry
NCT00326287 · 638 participants · Start Jun 2006 · Primary completion Jul 2007
Drug: Ceftobiprole medocaril; Ceftriaxone with or without Linezolid · For: Pneumonia
- Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus BacteremiaPivotal-lookingCompleted
Basilea PharmaceuticaIndustry
NCT03138733 · 390 participants · Start Aug 26, 2018 · Primary completion Mar 11, 2022
Drug: Ceftobiprole medocaril; Daptomycin · For: Staphylococcus Aureus Bacteremia
Sites: Chula Vista, California; West Palm Beach, Florida; Butte, Montana · 60 sites in all
- Ceftobiprole in the Treatment of Pediatric Patients With PneumoniaPivotal-lookingCompleted
Basilea PharmaceuticaIndustry
NCT03439124 · 138 participants · Start Nov 27, 2017 · Primary completion Mar 16, 2020
Drug: ceftobiprole medocaril; IV standard-of-care cephalosporin · For: Community-acquired Pneumonia (CAP); Hospital-acquired Pneumonia (HAP)
Sites: Pleven, Bulgaria; Plovdiv, Bulgaria; Rousse, Bulgaria · 19 sites in all
- Ceftobiprole in Hospital Acquired PneumoniaPivotal-lookingCompleted
Basilea PharmaceuticaIndustry
NCT00229008 · 106 participants · Start Nov 2005 · Primary completion May 2007
Drug: ceftobiprole plus placebo; linezolid plus ceftazidime · For: Pneumonia
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use12
- epilepsy10
- torsade de pointes6
- alveolar lung disease5
- gangrene5
- pneumonia necrotising5
- rash5
- agitation3
- clostridium difficile infection3
- diarrhoea3
- pancytopenia3
- pruritus3
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2017 | 1 |
| 2018 | 10 |
| 2019 | 1 |
| 2021 | 1 |
| 2024 | 3 |
| 2025 | 19 |
| 2026 | 22 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacokinetics and Safety of Ceftobiprole in Pediatric Patients.
Rubino CM, Polak M, Schröpf S, et al. · Pediatr Infect Dis J 2021 · Clinical Trial, Phase I, Clinical Trial, Phase III
- A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation.
Nicholson SC, Welte T, File TM, et al. · Int J Antimicrob Agents 2012 · Comparative Study, Multicenter Study
- A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections.
Noel GJ, Bush K, Bagchi P, et al. · Clin Infect Dis 2008 · Comparative Study, Multicenter Study
- A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia.
Awad SS, Rodriguez AH, Chuang YC, et al. · Clin Infect Dis 2014 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Istx
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.